Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.
 

Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Trastuzumab and Hyaluronidase-oysk for Breast Cancer

Feb 28, 2019, 12:14 PM
URL:
On February 28, the Food and Drug Administration approved trastuzumab and hyaluronidase-oysk injection for subcutaneous use (Herceptin Hylecta, Genentech Inc.) for the treatment of HER2-overexpressing breast cancer.

Leave a comment